| pubmed-article:10715299 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10715299 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:10715299 | lifeskim:mentions | umls-concept:C1518932 | lld:lifeskim |
| pubmed-article:10715299 | lifeskim:mentions | umls-concept:C1456649 | lld:lifeskim |
| pubmed-article:10715299 | lifeskim:mentions | umls-concept:C0023449 | lld:lifeskim |
| pubmed-article:10715299 | lifeskim:mentions | umls-concept:C0025677 | lld:lifeskim |
| pubmed-article:10715299 | lifeskim:mentions | umls-concept:C0348016 | lld:lifeskim |
| pubmed-article:10715299 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:10715299 | lifeskim:mentions | umls-concept:C1704419 | lld:lifeskim |
| pubmed-article:10715299 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:10715299 | pubmed:dateCreated | 2000-4-12 | lld:pubmed |
| pubmed-article:10715299 | pubmed:abstractText | To determine whether early intensification with 12 courses of intravenous (IV) methotrexate (MTX) and IV mercaptopurine (MP) is superior to 12 courses of IV MTX alone for prevention of relapse in children with lower-risk B-lineage acute lymphoblastic leukemia (ALL). | lld:pubmed |
| pubmed-article:10715299 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10715299 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10715299 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10715299 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10715299 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10715299 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10715299 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10715299 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:10715299 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:10715299 | pubmed:author | pubmed-author:NitschkeRR | lld:pubmed |
| pubmed-article:10715299 | pubmed:author | pubmed-author:SteuberC PCP | lld:pubmed |
| pubmed-article:10715299 | pubmed:author | pubmed-author:ShusterJ JJJ | lld:pubmed |
| pubmed-article:10715299 | pubmed:author | pubmed-author:CamittaBB | lld:pubmed |
| pubmed-article:10715299 | pubmed:author | pubmed-author:MahoneyD... | lld:pubmed |
| pubmed-article:10715299 | pubmed:author | pubmed-author:LauerSS | lld:pubmed |
| pubmed-article:10715299 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10715299 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:10715299 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10715299 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10715299 | pubmed:pagination | 1285-94 | lld:pubmed |
| pubmed-article:10715299 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:10715299 | pubmed:meshHeading | pubmed-meshheading:10715299... | lld:pubmed |
| pubmed-article:10715299 | pubmed:meshHeading | pubmed-meshheading:10715299... | lld:pubmed |
| pubmed-article:10715299 | pubmed:meshHeading | pubmed-meshheading:10715299... | lld:pubmed |
| pubmed-article:10715299 | pubmed:meshHeading | pubmed-meshheading:10715299... | lld:pubmed |
| pubmed-article:10715299 | pubmed:meshHeading | pubmed-meshheading:10715299... | lld:pubmed |
| pubmed-article:10715299 | pubmed:meshHeading | pubmed-meshheading:10715299... | lld:pubmed |
| pubmed-article:10715299 | pubmed:meshHeading | pubmed-meshheading:10715299... | lld:pubmed |
| pubmed-article:10715299 | pubmed:meshHeading | pubmed-meshheading:10715299... | lld:pubmed |
| pubmed-article:10715299 | pubmed:meshHeading | pubmed-meshheading:10715299... | lld:pubmed |
| pubmed-article:10715299 | pubmed:meshHeading | pubmed-meshheading:10715299... | lld:pubmed |
| pubmed-article:10715299 | pubmed:meshHeading | pubmed-meshheading:10715299... | lld:pubmed |
| pubmed-article:10715299 | pubmed:meshHeading | pubmed-meshheading:10715299... | lld:pubmed |
| pubmed-article:10715299 | pubmed:meshHeading | pubmed-meshheading:10715299... | lld:pubmed |
| pubmed-article:10715299 | pubmed:meshHeading | pubmed-meshheading:10715299... | lld:pubmed |
| pubmed-article:10715299 | pubmed:meshHeading | pubmed-meshheading:10715299... | lld:pubmed |
| pubmed-article:10715299 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10715299 | pubmed:articleTitle | Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study. | lld:pubmed |
| pubmed-article:10715299 | pubmed:affiliation | Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX, USA. dmahoney@msmail.his.tch.tmc.edu | lld:pubmed |
| pubmed-article:10715299 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10715299 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10715299 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:10715299 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
